IVF

INVO Fertility, Inc. (INVO Bioscience, Inc.) - 10-K Summary

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2008. INVO Bioscience, Inc. (the "Company") is a development-stage medical device company focused on the commercialization of the INVOcell, a patented device designed to treat infertility at a lower cost than In Vitro Fertilization (IVF). The Company completed a reverse merger with Emy's Salsa AJI Distribution Company, Inc. on December 5, 2008, becoming a publicly traded entity. The Company received CE marking in May 2008, permitting sales in the European Economic Area, Canada, and other regions, but has not yet received FDA clearance for the U.S. market.

Key Financial Metrics

Note: The Company reported a net loss of approximately $1.87 million for 2008. Cash used in operating activities was $1,066,629. The Company has a $50,000 line of credit with Century Bank, fully utilized as of year-end.

Material Changes vs. Prior Period

• Revenue Generation: The Company generated its first commercial revenue in Q4 2008 ($37,995) from the sale of 215 INVOcell units and 16 INVO Blocks. There was no revenue in 2007.
• Expense Surge: Operating expenses increased significantly from $210,520 in 2007 to $1,889,367 in 2008. This was driven by the hiring of the first full-time employees, stock-based compensation, travel for international market introduction, legal fees for the reverse merger ($375,000), and patent protection costs.
• Corporate Structure: The Company transitioned from a private entity (Bio X Cell, Inc.) to a public reporting company via a reverse merger with Emy's Salsa AJI Distribution Company, Inc. in December 2008.
• Inventory: Inventory increased from $0 in 2007 to $70,722 in 2008, consisting of work-in-process and finished goods.

Guidance, Outlook, and Risks

Outlook and Strategy: Management anticipates launching sales in Europe, Canada, Latin America, and the Middle East in 2009. The Company aims to complete clinical trials and file for FDA 510(k) clearance in late 2009, hoping to receive U.S. market clearance by 2010. The Company is actively seeking additional equity and debt financing to fund operations, as existing resources are insufficient to support the business plan.

Risks and Contingencies:

• Going Concern: The Company has a substantial working capital deficiency and recurring net losses. The auditors have expressed substantial doubt about the Company's ability to continue as a going concern without additional capital.
• Regulatory Approval: There is no assurance that the Company will receive FDA clearance by 2010 or ever. Failure to obtain clearance would prevent U.S. sales.
• Liquidity: The Company relies on the sale of common stock and related party loans to fund operations. There is no committed source of financing.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of December 31, 2008, due to limited resources and a small number of employees.

Key Facts for Investor Verification

• Cash Position: Verify the current cash balance and the status of the $50,000 line of credit, as the year-end cash balance was only $15,716.
• Capital Raising: Confirm whether the Company has secured the additional financing required to continue operations, given the "substantial doubt" regarding its going concern status.
• FDA Status: Monitor the progress of the 510(k) submission and clinical trial completion, as U.S. market entry is contingent on this clearance.
• Revenue Sustainability: Assess whether the initial sales of $38,000 in 2008 can be scaled, given the heavy reliance on international distributors and the high cost of sales relative to revenue volume.
• Related Party Transactions: Review the $96,462 note payable to Dr. Claude Ranoux (President) and the terms of its repayment or conversion.